1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

550 E Swedesford Rd Ste 400
Wayne, Pennsylvania 19087-1601
Phone: 16102256800


Teleflex Announces Second Quarter 2024 Earnings Conference Call Information
Jul 18, 2024 10:30am

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed Jetzt den vollständigen Artikel lesen

Piper upgrades Teleflex to overweight, cites expected EPS growth
Jul 01, 2024 17:54pm

No summary available.

Source:Seeking Alpha
Is it Wise to Hold Teleflex Stock in Your Portfolio Now?
Jun 28, 2024 15:43pm

Teleflex (NYSE: TFX ) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company''s market dominance in Central Venous Catheters and midlines categories is poised to continue, aiming to further increase market share by introducing new products. In addition, the sound solvency position is encouraging. Meanwhile, the impact of macroeconomic challenges on the company''s operations remains a concern. Competitive pressures may hinder Teleflex''s growth. In the past year, this Zacks Rank #3 (Hold) stock has declined 11.8% against the 3.4% growth of the industry and the 25.3% rise of the S&P 500 composite. The global provider of medical technologies has a market capitalization of $9.42 billion. TFX surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.5%. Let''s delve deeper. Tailwinds Strong Surge in the Interventional Segment: The Interventional product category, consisting of a range of applications to diagnose and administer treatment for coronary and peripheral vascular disease, generated 15.4% revenue growth in the first quarter of 2024.

US FDA classifies recall of Teleflex’s inflatable devices as ‘most serious’
Jun 13, 2024 21:27pm

(Reuters) - The U.S. Food and Drug Administration classified a recall of Teleflex''s inflatable devices that increase blood supply to the heart muscle …

US FDA classifies recall of Teleflex''s inflatable devices as ''most serious''
Jun 13, 2024 21:17pm

The U.S. Food and Drug Administration classified a recall of Teleflex''s inflatable devices that increase blood supply to the heart muscle as "most serious".

Peering Into Teleflex''s Recent Short Interest
Jun 04, 2024 18:00pm

Teleflex''s (NYSE: TFX ) short percent of float has risen 46.73% since its last report. The company recently reported that it has 865 thousand shares sold short , which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.72 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on